Savara (SVRA) Depreciation & Amortization (CF) (2010 - 2026)
Savara (SVRA) reported Depreciation & Amortization (CF) of $24000.0 for Q1 2026, down 20.0% year-over-year from $30000.0 in Q1 2025, and up 318.18% quarter-over-quarter from -$11000.0 in Q4 2025.
Savara (SVRA) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $24000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $24000.0, down 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $81000.0 (down 36.72% YoY), and the FY2025 annual result was $87000.0, down 33.08% from the prior year.
- Depreciation & Amortization (CF) climbed to $24000.0 in Q1 2026 per SVRA's latest filing, from -$11000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $35000.0 in Q3 2025 and troughed at -$11000.0 in Q4 2025.
- A 5-year average of $20588.2 and a median of $30000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) jumped 357.14% in 2023, then tumbled 134.38% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $7000.0 in 2022, then surged by 357.14% to $32000.0 in 2023, then changed by 0.0% to $32000.0 in 2024, then plunged by 134.38% to -$11000.0 in 2025, then jumped by 318.18% to $24000.0 in 2026.
- Business Quant data shows SVRA's Depreciation & Amortization (CF) at $24000.0 in Q1 2026, -$11000.0 in Q4 2025, and $35000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |